FAQs

Harvard is collaborating with Deerfield, an investment firm dedicated to advancing healthcare, to accelerate the translation of research in Harvard faculty laboratories into clinical therapeutics. Lab1636 is a Deerfield company that will support Harvard’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Lab1636 will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases.

Through Lab1636, Deerfield has committed up to $100 million in initial funding to support promising Harvard translational research. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Lab1636 projects that show commercial potential.

Principal Investigators whose principal employer is Harvard University or who have a faculty appointment at Harvard University and are therefore subject to Harvard’s institutional policies are eligible to apply.

To submit an application, please contact the Harvard Office of Technology Development.

No – We welcome applications from all therapeutic areas.